Leo A van Grunsven
Overview
Explore the profile of Leo A van Grunsven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
5138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merens V, Knetemann E, Gurbuz E, De Smet V, Messaoudi N, Reynaert H, et al.
JHEP Rep
. 2025 Jan;
7(1):101223.
PMID: 39758511
Background & Aims: The progression of chronic liver disease (CLD) is characterized by excessive extracellular matrix deposition, disrupting hepatic architecture and function. Upon liver injury, hepatic stellate cells (HSCs) differentiate...
2.
Hamouda A, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J, et al.
Nat Commun
. 2024 Dec;
15(1):10635.
PMID: 39639025
Local delivery of mRNA-based immunotherapy offers a promising avenue as it enables the production of specific immunomodulatory proteins that can stimulate the immune system to recognize and eliminate cancer cells...
3.
Krivec N, Couvreu de Deckersberg E, Lei Y, Al Delbany D, Regin M, Verhulst S, et al.
Cell Death Dis
. 2024 Nov;
15(11):852.
PMID: 39572522
Gain of 1q is a highly recurrent chromosomal abnormality in human pluripotent stem cells. In this work, we show that gains of 1q impact the differentiation capacity to derivates of...
4.
Coombes J, Manka P, Swiderska-Syn M, Vannan D, Riva A, Claridge L, et al.
Liver Int
. 2024 Oct;
45(4):e16131.
PMID: 39422353
Background And Aims: Osteopontin (OPN) promotes the ductular reaction and is a major driver of chronic liver disease (CLD) progression. Although CLD is characterised by the accumulation of inflammatory cells...
5.
Muturi H, Ghadieh H, Asalla S, Lester S, Belew G, Zaidi S, et al.
Mol Metab
. 2024 Aug;
88:102010.
PMID: 39168268
Objectives: Hepatic CEACAM1 expression declines with advanced hepatic fibrosis stage in patients with metabolic dysfunction-associated steatohepatitis (MASH). Global and hepatocyte-specific deletions of Ceacam1 impair insulin clearance to cause hepatic insulin...
6.
Cools L, Dastjerd M, Smout A, Merens V, Yang Y, Reynaert H, et al.
Biofabrication
. 2024 Jun;
16(3).
PMID: 38865994
The lack of adequate humanmodels that recapitulate the cellular composition and response of the human liver to injury hampers the development of anti-fibrotic drugs. The goal of this study was...
7.
De Smet V, Gurbuz E, Eysackers N, Dewyse L, Smout A, Dastjerd M, et al.
JHEP Rep
. 2024 May;
6(5):101036.
PMID: 38694958
Background & Aims: Chronic liver disease (CLD) remains a global health issue associated with a significant disease burden. Liver fibrosis, a hallmark of CLD, is characterised by the activation of...
8.
Muturi H, Ghadieh H, Asalla S, Lester S, Verhulst S, Stankus H, et al.
bioRxiv
. 2024 Apr;
PMID: 38617330
Objectives: Hepatic CEACAM1 expression declines with advanced hepatic fibrosis stage in patients with MASH. Global and hepatocyte-specific deletions of impair insulin clearance to cause hepatic insulin resistance and steatosis. They...
9.
Chai Y, To S, Simorgh S, Zaunz S, Zhu Y, Ahuja K, et al.
Adv Sci (Weinh)
. 2023 Dec;
11(5):e2304421.
PMID: 38037510
Although human pluripotent stem cell (PSC)-derived brain organoids have enabled researchers to gain insight into human brain development and disease, these organoids contain solely ectodermal cells and are not vascularized...
10.
Manka P, Coombes J, Sydor S, Swiderska-Syn M, Best J, Gauthier K, et al.
Liver Int
. 2023 Oct;
44(1):125-138.
PMID: 37872645
Objective: Progressive hepatic fibrosis can be considered the final stage of chronic liver disease. Hepatic stellate cells (HSC) play a central role in liver fibrogenesis. Thyroid hormones (TH, e.g. thyroxine;...